Masimo Q3 revenue beats expectations, helped by core healthcare business

Masimo

04/11/2025 21:47

Overview

Masimo Q3 2025 GAAP revenue grows 8.2%, beating analyst expectations

Non-GAAP EPS for Q3 grows 38% yr/yr, reflecting operational efficiency

Company, during qtr,  sold Sound United to Harman, proceeds used for stock repurchases

Outlook

Masimo expects for cont ops 2025 non-GAAP revenue of $1,510 to $1,530 mln

Company projects for cont ops 2025 non-GAAP EPS of $5.62 to $5.79 excluding tariffs impact

Result Drivers

SALES GROWTH - Co attributes Q3 revenue growth to positive momentum in core healthcare business and innovative products

OPERATING EFFICIENCY - Improved operating margin and EPS growth attributed to successful efficiency initiatives

STRATEGIC PARTNERSHIP - Expansion of partnership with Philips expected to support long-term growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$371.5 mln
$366.84 mln (8 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Masimo Corp is $182.50, about 20.6% above its November 3 closing price of $144.96

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 29 three months ago

Press Release: ID:nBw9k9y6ma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)